Sylentis Cleared to Begin Phase I/II Trial of Ocular Hypertension Drug

Sep 09, 2010

Premium

Sylentis said this week that it has received clearance from Spanish regulators to begin a second phase I/II trial of its siRNA-based ocular hypertension drug SYL040012.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Earlier this summer, the company completed a phase Ia trial, finding the agent to be safe and well-tolerated in healthy volunteers (GSN 7/8/2010).

The new trial will enroll patients with elevated intraocular pressure. Sylentis aims to develop SYL040012 as a glaucoma treatment.

Filed under

Gene Editing, Gene Silencing, & CRISPR

RNAi

siRNA

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.